Expert recommendations on clinical application of desvenlafaxine succinate
Desvenlafaxine succinate is a selective serotonin and norepinephrine reuptake inhibitor,which is the main active metabolite of the antidepressant venlafaxine.It is characterized by the absence of the need for titration,simple metabolism,low risk of drug interaction,and good tolerability.It was approved by the U.S.FDA in 2008 for the treatment of adult depression and was approved for marketing in China in 2023.Our recommendation writing group has searched domestic and foreign databases in order to provide guidance for the clinical application of desvenlafaxine succinate sustained-release tablets.This article systematically elaborates on the pharmacological effects,suitable populations,usage and dosage,as well as safety and drug resistance of the drug,helping clinicians to maximize patient benefits when using the drug for treatment.
major depressive disorderserotonin-norepinephrine reuptake inhibitorsdesvenlafaxine succinateexpert recommendations
万方数据
维普
